Editorial: PARP inhibitors resistance: new insights in ovarian cancer therapy

In recent years, the therapeutic landscape of ovarian cancer has nevertheless undergone a dramatic shift with the implementation of targeted therapies, including the antiangiogenic monoclonal antibody bevacizumab and the orally administered poly (ADP-ribose) polymerase inhibitors (PARPi). By harnessing the principle of synthetic lethality in tumors characterized by homologous recombination deficiency (HRD), especially those harboring BRCA1/2 genomic alterations, PARPi have provided meaningful clinical benefits. Of note, 25% of epithelial ovarian cancer cases are attributed to BRCA1/2 mutations, whereas almost 50% exhibit HRD.Yet, resistance emergence is rather inevitable leading to incurable disease recurrence and unfavorable prognosis. In light of this therapeutic challenge the Research Topic "PARP inhibitors resistance: new insights in ovarian cancer therapy" of Frontiers in Oncology comprises four insightful original articles that not only enhance our understanding of PARPi mechanism of action but also elucidate the complexity of the underlying resistance mechanisms, as well as explore emerging translational strategies in order to overcome these hurdles and improve patients' outcomes.In their comprehensive review, Kulkarni S. et al (1) Taken together, the aforementioned contributions provide a cohesive and future-oriented perspective on the biology and clinical translation of PARPi resistance. It has been our privilege to curate this Research Topic, which we sincerely hope will serve not only as a valuable scientific resource but also as a catalyst for future research, ultimately advancing the pursuit of personalized thus optimal treatment strategies for ovarian cancer patients.